

LeA 34494

Remarks / Arguments

Claims 13 and 14 are pending in this application. Claim 13 has been amended. Claim 10 has been cancelled.

Rejection under §103

Claims 10 and 13 stand rejected under §103 as being unpatentable over Haning (WO 98/40384, US 6,174,884) in view of Merck Manual, Home edition 1997, pages 12-15, 381-387, 398-402.

Claim 10 has been cancelled. The rejection of this claim is thus moot, and its withdrawal is accordingly requested. This cancellations leaves only claim 13 being rejected.

In particular, claim 13 has been rejected on grounds that the Haning reference teaches a method of treating cerebrovascular diseases (e.g., stroke) comprising administering to a patient a PDE-II inhibitory compound of formula (I), such as the compound represented by example 39 Haning, while the Merck reference teaches visual changes, dementia and depression can result from stroke.

For the reasons given in applicants' response dated December 28, 2004, Applicants believe Examiner's rejection is improper.

However, in order to expedite prosecution, Applicants have amended claim 13 to be directed to not read on stroke, but on

LeA 34494

a method for treating a disorder of perception, concentration, learning and/or memory, where said disorder of perception, concentration, learning and/or memory is a result of Alzheimer's disease.

Applicants believe the limitations of present claim 13 are not taught by the cited references and that the amendment overcomes the Examiner's rejections.


In view of the above amendments and arguments, this application is deemed to be in condition for allowance, and allowance is accordingly requested. Please charge any further fees due with this amendment to deposit account number 13-3372.

Respectfully submitted,

Reg. No.: 31018

Phone: (203) 812-2712

Date: 7/22/05



William F. Gray

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516-4175